LONDON, May 4, 2001 (PRIMEZONE) - Noonan/Russo
- - WEBCAST EVENT- - Noonan/Russo's BioInvestor Forum Friday 5 May 2001 from 15:00 BST www.noonanrusso.com
With presentations from:
OXiGENE Inc.
Presentation by Dr Bjorn Nordenvall, Chairman & CEO
Based in Stockholm and Boston, OXiGENE has a diverse portfolio of products to combat cancer and other major diseases. Their lead product, combrestatin, is the first in a new class of drugs - anti-tumor targeting agents - that starves tumors by shutting down their blood supply.
ProMetic Life Sciences Inc.
Presentation by Pierre Laurin, President, Chairman & CEO.
ProMetic, based in Quebec, owns proprietary enabling technology essential for use in therapeutics, large-scale drug purification, chemical genomics and proteomics, drug delivery and drug development.
LifePoint Inc.
Presentation by Linda Masterson, CEO.
Ontario-based LifePoint is developing the LifePoint(TM) Test System, a rapid, on-site diagnostic testing, screening and therapeutic drug monitoring device for initial use in law enforcement, workplace monitoring and emergency medical testing.
M&E Biotech A/S
Presentation by Soren Mouritsen, CEO and Jakob Schmidt, CFO.
M&E Biotech, based in Copenhagen, has two distinct technology platforms - AutoVac(TM), a therapeutic vaccine or 'pharmaccine' technology for the treatment of serious chronic diseases associated with the overexpression of pathogenic self-proteins and cancers, and CellScreen (TM), a 'reverse genomics' technology that manipulates biological processes inside mammalian cells.
IsoTis NV
Clemens van Blitterswijk, CEO and Pieter Wolters, CFO.
IsoTis, based in The Netherlands, aspires to become a global leader in the field of substitution medicine, fulfilling the need for human tissue and organ replacement with its hybrid technologies that are based on materials science, tissue engineering and biotechnology.
NeuroSearch A/S
Presentation by Jorgen Drejer, VP Drug Discovery Research Division and Henrik K Moltke, Director Investor Relations.
Copenhagen-based NeuroSearch is focused on the development of new drugs and procedures for the treatment of central nervous system (CNS) disorders, and has programs in the areas of monoamines, ligated ion channels, voltage operated ion channels and neuronal survival factors.
The webcast will be available on Noonan/Russo's website until 30 July. Individual presentations will also be available on company websites.
Attachments: http://reports.huginonline.com/819164/89443.pdf
Please click on the link to see the full press release.
Please call Noonan/Russo for further information on: +44-20-7726 4452